NCT01493869View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions

HealthyHepatic Impairment

Interventions

DRUG

cabozantinib

3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation

Trial Locations (1)

23249

McGuire VA Medical Center, Richmond

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY

NCT01493869 - Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects | Biotech Hunter | Biotech Hunter